SCHEDULE: Federated Hermes Discloses Arcturus Therapeutics Stake

Federated Hermes, Inc. and associated entities have filed a Schedule 13G, reporting beneficial ownership of 5.90% of Arcturus Therapeutics Holdings Inc. common stock as of September 30, 2026.

Summary

• Federated Hermes, Inc., along with the Voting Shares Irrevocable Trust and individuals Thomas R. Donahue, Ann C. Donahue, and J. Christopher Donahue, have filed an amended Schedule 13G.
• This filing reports their beneficial ownership of Arcturus Therapeutics Holdings Inc. common stock.
• The total aggregate amount beneficially owned is 1,678,069 shares, representing 5.90% of the class of securities.
• The filing specifies that Federated Hermes, Inc. is the parent holding company, and its subsidiaries act as investment advisers.
• The Voting Shares Irrevocable Trust holds all voting stock of Federated Hermes, Inc., with the Donahue family members acting as trustees.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this as a neutral filing, primarily an administrative update regarding beneficial ownership rather than a reflection of company performance or strategy.

Positives

• The filing clearly delineates the beneficial ownership structure, providing transparency regarding significant shareholdings.
• The reporting entities are established financial institutions and individuals, suggesting a potentially stable and informed investor base.

Negatives

• The filing does not contain any financial performance data or strategic updates for Arcturus Therapeutics Holdings Inc., limiting its insight into the company's operational health.
• The disclaimer of beneficial ownership for the managed funds indicates a complex ownership structure that may obscure direct control or influence.

Risks

• The filing does not explicitly mention any risks associated with Arcturus Therapeutics Holdings Inc. or the reporting entities' investment.
• Potential for future changes in beneficial ownership, which could impact share price or corporate control, is inherent in such filings but not detailed here.

Future Outlook

This filing is an informational disclosure regarding beneficial ownership and does not contain forward-looking statements or guidance for Arcturus Therapeutics Holdings Inc.

Management Comments

• In accordance with Rule 13d-4 under the Exchange Act, Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue declare that this report should not be construed as an admission that any of them is the beneficial owner of the securities held by any of the Managed Funds, and each of Federated Hermes, Inc.; the Voting Shares Irrevocable Trust; Thomas R. Donahue; Ann C. Donahue; and J. Christopher Donahue expressly disclaim beneficial ownership of such securities.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are common for institutional investors and investment funds accumulating significant stakes in publicly traded companies. This filing indicates a substantial, though not controlling, ownership position by Federated Hermes entities in Arcturus Therapeutics, a biotechnology company.

Stakeholder Impact

• Shareholders: Increased transparency regarding a significant beneficial owner, potentially influencing market perception.
• Management of Arcturus Therapeutics: Awareness of a substantial institutional investor's holdings.

Next Steps

• Continued monitoring of Arcturus Therapeutics Holdings Inc. by Federated Hermes entities.
• Potential future amendments to the Schedule 13G if beneficial ownership changes significantly.

Key Dates

Keywords

Arcturus Therapeutics Holdings Inc., Federated Hermes, Schedule 13G, Beneficial Ownership, Common Stock, Investment Adviser, Holding Company, Voting Shares Irrevocable Trust